论文部分内容阅读
目的观察匹多莫德口服液治疗反复呼吸道感染(RRSI)患儿的疗效。方法 89例RRSI患儿中反复上呼吸道感染48例,反复下呼吸道感染41例。89例(病例组)分为观察组和对照组,二组均给予青霉素及利巴韦林注射液常规治疗;观察组在上述常规治疗的基础上,同时给予匹多莫德口服液。观察二组临床疗效,并测定IgA,IgG,IgM,CD3+,CD4+,CD8+,CD4+/CD8+,IL-2,NK的水平。结果治疗后观察组总有效率90.0%(45/50),对照组总有效率33.3(13/39),二组比较差异有统计学意义(P<0.01)。观察组治疗后,IgA,IgG,IgM,CD3+,CD4+,CD8+,CD4+/CD8+,IL-2,NK值均明显增加(P<0.01)。结论匹多莫德口服液用于防治小儿RRSI有明显疗效,能有效地改善免疫学指标,无明显不良反应。
Objective To observe the curative effect of pidotimod oral solution in children with recurrent respiratory tract infection (RRSI). Methods 48 cases of recurrent upper respiratory tract infection and repeated lower respiratory tract infection in 89 children with RRSI were studied. 89 cases (case group) were divided into observation group and control group. Both groups were given routine treatment with penicillin and ribavirin injection. The observation group was given Pidotimod oral solution on the basis of the above conventional treatment. The clinical effects of the two groups were observed and the levels of IgA, IgG, IgM, CD3 +, CD4 +, CD8 +, CD4 + / CD8 +, IL-2 and NK were measured. Results After treatment, the total effective rate was 90.0% (45/50) in the observation group and 33.3 (13/39) in the control group. The difference between the two groups was statistically significant (P <0.01). After treatment, IgA, IgG, IgM, CD3 +, CD4 +, CD8 +, CD4 + / CD8 +, IL-2 and NK in the observation group were significantly increased (P <0.01). Conclusion Pidotimod oral solution for the prevention and treatment of children with RRSI significant effect, can effectively improve the immunological indicators, no significant adverse reactions.